EFFECT OF PROLONGED TREATMENT WITH BIOLOGICAL THERAPY IN PATIENTS WITH ULCERATIVE COLITIS WITH CONCOMITENT JOINT DAMAGE

Abstract

OBJECTIVE: The aim: Is to compare the effects of tofacitinib, adalimumab and budesonide clinical and laboratory signs of patients with moderate UC with concomitant articular syndrome. PATIENTS AND METHODS: Materials and methods: 100 patients with moderately severe UC. Patients were divided into 2 groups. The I group consisted of patients with UC, which were treated with tofacitinib 10mg bid (TOF; n=28). II group consisted of patients who were treated with adalimumab with a starting dose of 160 mg and 80 mg on the 2nd week of treatment, after which they received a subsequent dosage of 40 mg per week (ADA; n=32). Patients in the III group received budesonide 9mg qd (BUD; n=40). RESULTS: Results: As a result of treatment in the TOF research group, leukocyte and CRP levels decreased compared to readings before treatment (from 13.6±2.4*109/l and 1698 14.0±1.4mg/l to 10.6±1.2*109/l and 11.0±2.1 mg/l respectively, p<0.05). Hemoglobin levels in this group slightly increased (from 104.2±9.2 g/l to 126.1±10.2 g/l, p<0.05). Among ADA patients, there was also an improvement in laboratory signs: leukocyte and CRP levels decreased (from 13.8±2.8*109/l and 16.0±1.2 mg/l to 6.0±2.2*109 /l and 11.8±1.2 mg/l respectively, r<0.05), hemoglobin increased (from 103.8±8.2 g/l to 118.6±8.6 g/l/l r<0.05). CONCLUSION: Conclusions: Tofacitinib and adalimumab in the treatment of patients with ulcerative colitis of moderate severity with concomitant joint damage showed a higher clinical and laboratory effectiveness compared to treatment with budesonide.